GLP-2: A Literature Course

This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision. Nothing below is a protocol, a recommendation or an endorsement. It is a structured reading of published papers on glucagon-like peptide-2 (GLP-2), organised into six modules so that a reader can see what researchers actually measured, in what model, and where the published record stops.

Module 1: What GLP-2 Is and How It Has Been Studied

Definition and class. GLP-2 is a 33-amino-acid peptide hormone in the glucagon superfamily. It is encoded within the proglucagon gene and liberated by prohormone convertase processing in intestinal enteroendocrine L-cells, the same cell population that releases GLP-1. Because the two peptides share an origin, much of the literature discusses them together; a 2021 review of GLP-1 and intestinal diseases situated both peptides within gut endocrine physiology and the enteroendocrine response to luminal nutrients (PMID 33916501).

Origin and secretion. Release is classically postprandial. A 2019 study in Arteriosclerosis, Thrombosis, and Vascular Biology examined how glucose and GLP-2 mobilise intestinal triglyceride, and reported that the two stimuli acted through distinct mechanisms rather than a single shared pathway (PMID 31294621). A 2022 study in Obesity Surgery described peptide tyrosine-tyrosine (PYY) as a trigger for GLP-2-mediated intestinal hypertrophy after Roux-en-Y gastric bypass, placing GLP-2 downstream of other gut signals in that surgical model (PMID 36301409).

Forms encountered in the literature. Papers refer to endogenous GLP-2, synthetic native GLP-2 used as a research tool, degradation-resistant analogues used clinically, and dual agonists engineered to hit more than one receptor. A 2022 Hepatology paper described a GLP-1/GLP-2 receptor dual agonist developed for NASH with a stated aim of targeting the gut–liver axis and microbiome (PMID 34773257), and a 2022 paper in the Annals of the New York Academy of Sciences studied dapiglutide, a dual GLP-1 and GLP-2 receptor agonist, in murine short bowel (PMID 35580981). GLP-2 has also been measured outside the body: a 2021 Heliyon study reported the presence of GLP-2 in bovine colostrum and transition milk (PMID 34041395).

Limits of the evidence in Module 1

The papers above define the peptide and its sources but do not establish equivalence between native GLP-2, analogues and dual agonists. A finding in a dual-agonist study cannot be attributed to GLP-2 alone, and the colostrum measurement described concentration in milk, not any downstream human effect.

Module 2: Mechanism as Described in the Literature

GLP-2 signals through the GLP-2 receptor, which the literature locates on non-epithelial cells of the intestine rather than directly on enterocytes, implying indirect mediators. Published work has pursued several such mediators.

Trophic and barrier effects

The murine short bowel study of dapiglutide reported that the dual GLP-1/GLP-2 receptor agonist promoted barrier function, framing GLP-2 receptor signalling as relevant to intestinal permeability and not only to mucosal mass (PMID 35580981). The post-bypass rodent work reported intestinal hypertrophy mediated by GLP-2 and triggered upstream by PYY (PMID 36301409).

Lymphatic and lipid handling

A 2025 study in the American Journal of Physiology – Gastrointestinal and Liver Physiology identified serotonin as a downstream effector of GLP-2 and reported that this axis enhanced lacteal contractility and lymph flow (PMID 40953149). That mechanism sits alongside the 2019 finding that GLP-2 mobilised intestinal triglyceride stores by a mechanism distinct from that used by glucose (PMID 31294621).

Gut–liver and systemic signalling

A 2024 Gut Microbes study reported that an impaired postprandial GLP-2 response was associated with enhanced endotoxemia, systemic inflammation and kidney injury in metabolic dysfunction-associated steatohepatitis, and examined phospholipid curcumin (Meriva) in that setting (PMID 39620369). The dual GLP-1/GLP-2 agonist NASH paper made the gut–liver axis and microbiome its explicit target (PMID 34773257).

Intracellular pathways outside the gut

A 2024 paper in Archives of Gerontology and Geriatrics reported that GLP-2 ameliorated D-galactose-induced muscle aging through IGF-1/PI3K/Akt/FoxO3a signalling in C2C12 cells and in mice (PMID 38692155). A 2025 paper in the Journal of Orthopaedic Surgery and Research reported that GLP-2-carrying exosomes upregulated miR-378a-3p and inhibited osteoclastic differentiation and NF-κB–MAPK pathway activity in an osteoporosis model (PMID 40855458).

Limits of the evidence in Module 2

Mechanistic pathways described in cultured myotubes, exosome preparations and rodent intestine are model-specific. The literature cited here does not demonstrate that the same pathways operate at the same magnitude in humans, and association between a blunted GLP-2 response and inflammation does not establish direction of causation.

Module 3: Reported Outcomes by Study

The table below summarises models, endpoints and reported results as stated in each paper. It is a reading aid, not a ranking, and no benefit is implied or promised.

Short bowel syndrome as the most developed clinical thread

The clinical literature on GLP-2 is densest in intestinal failure. A 2025 paper in Pediatric Surgery International described three years of experience with a GLP-2 analog used within intestinal rehabilitation for pediatric-onset short bowel syndrome (PMID 40875041). Preclinical work in the same disease space reported barrier-function effects of a dual GLP-1/GLP-2 agonist in murine short bowel (PMID 35580981).

Metabolic and extraintestinal threads

A 2025 Nature Metabolism paper reported that GLP-2 prevented antipsychotic-induced metabolic dysfunction in mice, an endpoint set in a drug-induced model rather than in spontaneous obesity (PMID 40114026). Bone and skeletal muscle endpoints appeared in the exosome osteoporosis study (PMID 40855458) and the C2C12/mouse aging study (PMID 38692155).

Limits of the evidence in Module 3

Most of the outcomes listed are from rodent or cell models. Single-centre clinical experience reports, such as the pediatric short bowel series (PMID 40875041), are uncontrolled by design. Positive findings in induced-disease models do not forecast outcomes in healthy individuals, and none of these papers tested GLP-2 for general wellness, body composition or performance.

Module 4: GLP-2 Side Effects: What Studies Report

Adverse-event reporting in the verified GLP-2 literature is limited, and this module reports only what the cited papers describe rather than extrapolating from related drug classes.

The most directly relevant safety-adjacent source is the three-year clinical experience with a GLP-2 analog in pediatric-onset short bowel syndrome, in which tolerability and management over prolonged analog exposure were part of the reported rehabilitation experience (PMID 40875041). Because GLP-2 receptor agonism is a trophic signal for intestinal mucosa, the mechanistic literature on hypertrophy is often read alongside safety discussion: researchers reported GLP-2-mediated intestinal hypertrophy after Roux-en-Y gastric bypass in a rodent model (PMID 36301409), and a separate group reported barrier-function changes with dual GLP-1/GLP-2 receptor agonism in murine short bowel (PMID 35580981).

Other cited papers describe physiological changes that are endpoints rather than adverse events: mobilisation of intestinal triglyceride stores (PMID 31294621) and increased lacteal contractility and lymph flow driven by serotonin downstream of GLP-2 (PMID 40953149). Whether such changes would be desirable or unwanted depends entirely on clinical context, and the cited studies did not adjudicate that question.

Limits of the evidence in Module 4

None of the verified papers is a dedicated safety trial, none reports a systematic adverse-event table for healthy human volunteers, and long-term oncological surveillance data are not present in the sources cited here. A reader should treat the absence of reported harm in a mechanistic mouse study as absence of measurement, not as evidence of safety.

Module 5: Pharmacokinetics Where Data Exist

Native GLP-2 is described in the endocrine literature as short-lived in circulation because of dipeptidyl peptidase-4 cleavage, which is the stated rationale for degradation-resistant analogues and for engineered dual agonists. The verified papers here do not publish half-life values, clearance constants or bioavailability figures for GLP-2 in humans, so no such numbers are reproduced on this page.

What the cited literature does describe is exposure context. Secretion is postprandial and can be blunted in disease: researchers reported an impaired postprandial GLP-2 response in metabolic dysfunction-associated steatohepatitis (PMID 39620369). Sustained receptor engagement has been approached through molecular design, as in the GLP-1/GLP-2 dual agonist developed for NASH (PMID 34773257) and dapiglutide in murine short bowel (PMID 35580981). Alternative delivery has also been explored: the osteoporosis study used exosomes as carriers for GLP-2 (PMID 40855458). Measurable GLP-2 has additionally been quantified in bovine colostrum and transition milk, indicating that the peptide is detectable in biological fluids outside plasma (PMID 34041395).

Limits of the evidence in Module 5

No dose, dosing interval or concentration is stated on this page because the verified source list does not support one. Pharmacokinetic behaviour of an analog or dual agonist should not be assumed to mirror native GLP-2, and rodent kinetics do not transfer to humans.

Module 6: Regulatory Status, Stated Factually

Regulatory categories differ sharply from research categories, and the distinction matters when reading peptide literature.

• Approved analogue products. A GLP-2 analog has an established place in intestinal rehabilitation practice for short bowel syndrome, as reflected in the three-year clinical experience report in pediatric-onset disease (PMID 40875041). Prescribing is a regulated clinical activity conducted by licensed clinicians.
• Investigational agents. Dual GLP-1/GLP-2 receptor agonists, including the NASH-directed agent (PMID 34773257) and dapiglutide (PMID 35580981), appear in the literature as development-stage molecules rather than as established therapies.
• Research-use-only material. Synthetic native GLP-2 supplied for laboratory work is labelled research use only. RUO material is not an approved medicine, is not manufactured to pharmaceutical standards and is not intended for human administration.
• Compounding. Compounded preparations are made by licensed pharmacies under specific statutory conditions and are distinct from approved products; regulators periodically reclassify which substances may be compounded.

This section states regulatory categories for context and is not legal advice.

Limits of the evidence in Module 6

Regulatory status varies by jurisdiction and changes over time. The papers cited in this course are scientific studies, not regulatory documents, and they do not determine the legal status of any material anywhere.

What the Studies Did Not Test

Closing a literature course means naming the gaps. Across the sources cited here, researchers did not test GLP-2 in healthy adults for general wellness, longevity, athletic performance or cosmetic outcomes. The muscle-aging work was conducted in C2C12 cells and D-galactose-treated mice (PMID 38692155); the metabolic work was conducted in mice with antipsychotic-induced dysfunction (PMID 40114026); the bone work used an exosome delivery system (PMID 40855458). None of these were self-administration studies, none compared unapproved material with approved analogues, and none reported long-term human safety surveillance. The gut-focused literature, including the review of GLP-1 and intestinal diseases (PMID 33916501), frames GLP-2 within disease physiology rather than enhancement.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question. It summarises published findings so that readers can locate and read the primary sources themselves.

References

• A GLP-1/GLP-2 receptor dual agonist to treat NASH: Targeting the gut-liver axis and microbiome (Hepatology, 2022)
• GLP-2 ameliorates D-galactose induced muscle aging by IGF-1/Pi3k/Akt/FoxO3a signaling pathway in C2C12 cells and mice (Archives of Gerontology and Geriatrics, 2024)
• GLP-2 prevents antipsychotics-induced metabolic dysfunction in mice (Nature Metabolism, 2025)
• GLP-1 and Intestinal Diseases (Biomedicines, 2021)
• Impaired postprandial GLP-2 response enhances endotoxemia, systemic inflammation, and kidney injury in metabolic dysfunction-associated steatohepatitis (MASH): effect of phospholipid curcumin meriva (Gut Microbes, 2024)
• GLP-2-carrying exosomes alleviate osteoporosis by upregulating miR-378a-3p to inhibit osteoclastic differentiation and NF-κB-MAPK pathway (Journal of Orthopaedic Surgery and Research, 2025)
• Glucagon-like peptide 2 (GLP-2) in bovine colostrum and transition milk (Heliyon, 2021)
• Serotonin, a downstream effector of GLP-2, enhances lacteal contractility and lymph flow (American Journal of Physiology - Gastrointestinal and Liver Physiology, 2025)
• Three-year experience with GLP-2 analog in intestinal rehabilitation for pediatric-onset short bowel syndrome (Pediatric Surgery International, 2025)
• Glucose and GLP-2 (Glucagon-Like Peptide-2) Mobilize Intestinal Triglyceride by Distinct Mechanisms (Arteriosclerosis, Thrombosis, and Vascular Biology, 2019)
• Peptide Tyrosine-Tyrosine Triggers GLP-2-Mediated Intestinal Hypertrophy After Roux-en-Y Gastric Bypass (Obesity Surgery, 2022)
• The dual GLP-1 and GLP-2 receptor agonist dapiglutide promotes barrier function in murine short bowel (Annals of the New York Academy of Sciences, 2022)